| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | -0.44 | 0.007 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.3 | 0.007 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.097 | 0.007 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | 0.096 | 0.007 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.096 | 0.008 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.097 | 0.008 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | -0.093 | 0.009 |
| mRNA | selumetinib:PLX-4032 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.093 | 0.009 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.31 | 0.01 |
| mRNA | MP470 | GDSC1000 | pan-cancer | AAC | 0.094 | 0.01 |